Sign in to view content

Elevatum Study Design and Rationale: A Phase 4 Trial of Faricimab (VABYSMO) in Underrepresented Patients With Diabetic Macular Edema

Joseph M. Coney, MD, FASRS

Video
Published 2023

Related

New Tool for Predicting the 3-Year Risk of Vision-Threatening Diabetic Retinopathy in Patients With Type 2 Diabetes Mellitus
Bobeck S Modjtahedi, MD
Annual Meeting Talks
2022
Treatment of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy With Intravitreal Aflibercept Injection: 52-Week Results From PANORAMA
W. Lloyd Clark, MD, FASRS
Annual Meeting Talks
2019
Time to Retinal Fluid Control With Faricimab vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials
Aleksandra V. Rachitskaya, MD, FASRS
Annual Meeting Talks
2023

Category: Diabetic Retinopathy

See more